secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENANTA PHARMACEUTICALS INC (ENTA)
CIK:        0001177648
Form:       8-K
Filed at:   2022-06-22T23:59:59+00:00
Accession:  0001193125-22-178106
Event type: litigation
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Enanta sues Pfizer for patent infringement over Paxlovid, seeks damages only
----------------------------------------------------------------------------

- Filed suit against Pfizer in U.S. District Court for Massachusetts over U.S. Patent No. 11,358,953 covering coronavirus protease inhibitors.
- Patent was awarded earlier in June 2022 based on a July 2020 application; Enanta claims Pfizer's Paxlovid infringes.
- Enanta states it will not seek an injunction or take action to block production, sale, or distribution of Paxlovid.
- Enanta seeks 'fair compensation' for Pfizer's use of the coronavirus protease inhibitor claimed in the '953 patent.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1177648/000119312522178106/0001193125-22-178106-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1177648/000119312522178106/d356525d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-178106

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer